Article

Systematic Review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis

2020-06-18

Abstract excerpt

<title>Abstract</title> <p>Background There is currently no formal prostate cancer screening programme in the UK. Early detection using age-based prostate-specific antigen (PSA) testing is unlikely to be cost-effective due to limited mortality benefit and harms associated with overdetection. However, the discovery of new prostate cancer specific biomarkers and more accurate diagnostic strategies (e.g. magnetic r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2555142d-4f98-59da-a898-29d0e548d892
DOI: 10.21203/rs.3.rs-32349/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Systematic Review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosisDOI 10.21203/rs.3.rs-32349/v1Read

The benefits, harms, and cost-effectiveness of age-based and risk-stratified screening for prostate cancer with MRISemantic proximity Read

Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales.Semantic proximity Read

Impact of a new diagnostic pathway for prostate cancer - From systematic transrectal to targeted MRI fusion transperineal biopsiesSemantic proximity Read

Screening for prostate cancer using PSA with and without MRI: systematic reviews with meta-analysisSemantic proximity Read

A bibliometric analysis of use of Machine learning and Artificial intelligence in Prostate Cancer DetectionSemantic proximity Read

Statistical analysis plan for the TRANSLATE (TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation of potentially clinically significant prostate cancer) multicentre randomised controlled trialSemantic proximity Read

Optimizing Detection of Clinically Significant Prostate Cancer through Nomograms incorporating MRI, Clinical Features, and Advanced Serum BiomarkersSemantic proximity Read

How Are We Evaluating the Cost-Effectiveness of Companion Biomarkers for Targeted Cancer Therapies? A Systematic ReviewSemantic proximity Read

Cancer detection and complications of freehand cognitive MRI/US fusion transperineal biopsy of the prostate under local anaesthesia without antibiotic prophylaxis in an in- office setting: a consecutive series of 538 patientsSemantic proximity Read

Implementation and first results of the Czech nationwide prostate cancer screening pilot programmeSemantic proximity Read

Bivariate Diagnostic Paired Meta-Analysis at the Patient Level: Direct Validation of PSMA-PET against Conventional Imaging Across All T/N/M Staging Dimensions in Primary Intermediate- to High-Risk Prostate CancerSemantic proximity Read

MRI-Targeted Prostate Biopsy Introduces Grade Inflation and OvertreatmentSemantic proximity Read